Rankings
Pricing
Log In
Free Trial
US-listed companies
Liminal BioSciences Inc.
Liminal BioSciences Inc.
LMNL
Market cap
P/E ratio
Add to your list
Add to your list
Back to summarized table
B
M
K
CAD
Annual
Quarterly
Download CSV
Income statement
Balance sheet
Cash flow
Dec 31,
2019
Dec 31,
2020
Dec 31,
2021
Dec 31,
2022
Revenues
-
-
1
0
Research and development expense
75
57
18
15
Administration expenses
-
-
32
18
Gain on foreign exchange
-1
-1
-1
-3
Finance costs
14
9
6
1
Gain Loss On Extinguishments Of Liabilities
92
-0
-0
0
Change in fair value of financial instruments measured at fair value through profit or loss (note 15)
1
1
10
2
Impairment losses (note 23)
12
21
0
-
Loss from continuing operations before income taxes
-234
-122
-45
-29
Current income tax
-
-0
-
-1
Deferred income tax
-
-0
0
0
Income tax expense (recovery) from continuing operations (note 24)
-0
-0
0
-1
Net loss from continuing operations
-234
-122
-45
-29
Gain On Sale Of Subsidiary
26
3
140
-1
Net Income From Discontinued Operations
1
-
-83
30
Total income (loss) from discontinued operations
27
3
57
30
Net income (loss)
-207
-119
12
1
Non-controlling interests in continuing operations (note 18)
-1
-1
-1
0
- Continuing operations
-233
-121
-44
-29
Net income (loss) from discontinued operations during the year
27
3
57
30
Total Net loss attributable to owners of the parent from continuing and discontinued operations
-206
-118
13
1
Net income (loss)
-207
-119
12
1
From continuing operations
-
-
-1.47
-9.36
From discontinued operations
-
-
1.9
9.52
Total income per share
-
-
0.43
0.16